BLUSENSE DIAGNOSTICS APS - CVR: 36059184

2021, DKK

18.07.2022

Bruttoresultat

-12.489'

Primær drift

-31.904'

Årets resultat

-26.528'

Aktiver

38.264'

Kortfristede aktiver

34.446'

Egenkapital

27.219'

Afkastningsgrad

-83 %

Soliditetsgrad

71 %

Likviditetsgrad

312 %

Resultat

18.07.2022

Årsrapport	2021 18.07.2022	2020 03.06.2021	2019 28.05.2020	2018 12.06.2019	2017 04.06.2018	2016 02.06.2017
Nettoomsætning
Bruttoresultat	-12.489.000	-8.577.000	-12.218.000	-9.396.000	-8.750.000	0
Resultat af primær drift	-31.904.000	-28.780.000	-33.284.000	-22.587.000	-17.885.000	-10.535.000
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0
Finansielle indtægter	6.000	4.000	0	69.000	148.000	16.000
Finansieringsomkostninger	-130.000	-104.000	-173.000	-263.000	-88.000	-9.000
Andre finansielle omkostninger	0	0	0	0	0	0
Resultat før skat	-32.028.000	-28.880.000	-33.457.000	-22.781.000	-17.825.000	-10.528.000
Resultat	-26.528.000	-23.380.000	-27.957.000	-18.778.000	-14.496.000	-7.850.000
Forslag til udbytte	0	0	0	0	0	0

Aktiver

18.07.2022

Årsrapport	2021 18.07.2022	2020 03.06.2021	2019 28.05.2020	2018 12.06.2019	2017 04.06.2018	2016 02.06.2017
Kortfristede varebeholdninger	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	9.571.000	6.697.000	6.101.000	4.223.000	4.569.000	3.677.000
Likvider	23.510.000	9.743.000	29.597.000	6.670.000	8.617.000	3.384.000
Kortfristede aktiver	34.446.000	16.440.000	35.698.000	10.893.000	13.186.000	7.061.000
Immaterielle aktiver og goodwill	0	0	0	0	0	0
Finansielle anlægsaktiver	2.432.000	2.600.000	2.510.000	2.336.000	2.203.000	2.081.000
Materielle aktiver	1.386.000	0	0	0	968.000	445.000
Langfristede aktiver	3.818.000	4.121.000	3.269.000	3.096.000	3.171.000	2.526.000
Aktiver	38.264.000	20.561.000	38.967.000	13.989.000	16.357.000	9.587.000

Aktiver

18.07.2022

Passiver

18.07.2022

Årsrapport	2021 18.07.2022	2020 03.06.2021	2019 28.05.2020	2018 12.06.2019	2017 04.06.2018	2016 02.06.2017
Forslag til udbytte	0	0	0	0	0	0
Egenkapital	27.219.000	5.319.000	-8.551.000	7.893.000	12.691.000	6.939.000
Hensatte forpligtelser	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0
Anden langfristet gæld	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	1.702.000	676.000	1.922.000	944.000	2.977.000	0
Kortfristede forpligtelser	11.045.000	5.954.000	17.727.000	6.096.000	3.666.000	0
Gældsforpligtelser	11.045.000	15.242.000	47.518.000	6.096.000	3.666.000	2.648.000
Forpligtelser	11.045.000	15.242.000	47.518.000	6.096.000	3.666.000	2.648.000
Passiver	38.264.000	20.561.000	38.967.000	13.989.000	16.357.000	9.587.000

Passiver

18.07.2022

Nøgletal

18.07.2022

Årsrapport	2021 18.07.2022	2020 03.06.2021	2019 28.05.2020	2018 12.06.2019	2017 04.06.2018	2016 02.06.2017
Afkastningsgrad	-83,4 %	-140,0 %	-85,4 %	-161,5 %	-109,3 %	-109,9 %
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-97,5 %	-439,6 %	326,9 %	-237,9 %	-114,2 %	-113,1 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-24.541,5 %	-27.673,1 %	-19.239,3 %	-8.588,2 %	-20.323,9 %	-117.055,6 %
Soliditestgrad	71,1 %	25,9 %	-21,9 %	56,4 %	77,6 %	72,4 %
Likviditetsgrad	311,9 %	276,1 %	201,4 %	178,7 %	359,7 %	Na.

Resultat

18.07.2022

Gæld

18.07.2022

Årsrapport

18.07.2022

Nyeste:01.01.2021- 31.12.2021(offentliggjort: 18.07.2022)

Information om virksomhedens regnskabsklasse:The annual report of BluSense Diagnostics ApS for 2021 has been prepared in accordance with the provisions applying to reporting class B entities under the Danish Financial Statements Act with opt-in of specific provisions for reporting class C.

Beretning

18.07.2022

Dato for ledelsens godkendelse af årsrapporten:2022-06-28

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The Board of Directors and the Executive Board have today discussed and approved the annual report of BluSense Diagnostics ApS for the financial year 1 January – 31 December 2021.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:BluSense Diagnostics is a young and dynamic medtech company, born as a spin-off from the Technical University of Denmark (DTU), one of the leading technical universities of Northern Europe. The technological innovation is based on the opto-magnetic readout which is part of BluSense’s core IP. BluSense has developed an innovative nanotechnology-based point-of-care blood testing platform for the diagnostics of infectious diseases. The platform is based on a reader (BluBox) and single-use blood test cartridges (ViroTrack), specifically designed for targeting different viruses. BluSense’s diagnostic tests are based on its proprietary technology called Immuno Magnetic Assay (IMA). IMA is compatible with virtually any biomarker and more than 20 peer-reviewed papers have been published in scientific journals demonstrating the application of IMA for a wide range of applications. The versatility of the technology will allow BluSense to rapidly expand the test portfolio to other diseases such as COVID-19, yellow fever or chagas. All of the new tests will be compatible with BluBox such that customers can easily perform new test as they become available without the need to change hardware. BluSense currently has four CE marked products on the market: BluBox, ViroTrack Acute Dengue NS1, ViroTrack Comob Dengue and ViroTrack Sero Covid Total Ab. In 2021 in response to the COVID-19 pandemic, BluSense launched ViroTrack Sero Covid Total Ab, a test to quantify the amount of antibodies against COVID-19 of an individual following vaccination or infection with the virus. The test has been launched in Italy, Ireland and Germany so far and the company expects to enter other EU and non-EU markets within 2022.